$VERX

Vertex Analysts Lower Their Forecasts Following Q2 Results - Vertex (NASDAQ:VERX)

Vertex Inc (NASDAQ:VERX) reported Q2 EPS of $0.20, above the $0.19 consensus, and sales of $203.97 million, above $202.30 million. For Q3, it guided revenue of $208.0 million to $211.0 million versus $211.70 million expected. Shares fell about 2% to $13.13 premarket as analysts lowered forecasts and adjusted price targets.

Original reporting
Published Aug 4, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 3:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$VERX
Bearish
medium confidence
Mentioned
$VERX
Relevance
7/10
alphai data visualization · based on benzinga.com
Decision brief

The 30-second read

$VERXBearishMed
01

Why it matters

Traders can focus on the forward revenue guide versus consensus as the immediate driver of sentiment, given the pre-market decline despite the reported Q2 beat.

02

Market read

Forward guidance below consensus is the actionable takeaway, likely driving near-term positioning more than the backward-looking Q2 beat.

03

What to watch

The article does not include margins, cash flow, backlog, or segment detail, so the guidance miss may be less severe than it appears without profitability context.

Relevance 7/10Novelty 6/10Timing: pre-market today

Background

The piece summarizes Vertex’s Q2 results and provides a Q3 sales outlook relative to consensus, plus a note that analysts adjusted price targets after the earnings release.

Company-level read

Ticker impact

$VERXBearishMedium confidence
Context

Vertex reported Q2 EPS of $0.20 and sales of $203.97M, but guided Q3 sales below consensus, with shares down about 2% pre-market.

Expected impact

Bearish bias for the next session as the below-consensus Q3 sales outlook likely outweighs the Q2 beat for traders focused on forward revenue.

Evidence & confidence

The article provides explicit Q3 sales guidance ($208.0M-$211.0M) versus market estimates ($211.696M) and notes a pre-market drop, indicating the market is reacting to forward numbers.

Market effects

Limited spillover; this is company-specific earnings and forward guidance rather than a sector-wide signal.

None indicated beyond US pre-market reaction.

None indicated.

Counterpoint

The Q2 beat on both EPS and sales could still support the stock if investors believe the Q3 guide is conservative or driven by timing rather than demand weakness.

Key entities

  • Vertex Inc

    Reported Q2 EPS and sales beats, but issued Q3 sales guidance below market estimates; shares fell ~2% pre-market.

Related articles

$VERXMedAI 8/10

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.

$VERXMedAI 8/10

Why is Vertex stock sliding today?

Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.

$VERXMed

Vertex stock tumbles on cloud growth miss, price target cuts

Vertex Inc. (NASDAQ:VERX) shares dropped 13.2% after its Q2 results missed cloud growth expectations and analysts cut price targets. DA Davidson lowered its target to $12 from $15, citing slower cloud conversions and reduced FY26 cloud growth guidance to 18% from 25%. Other analysts also adjusted targets following guidance and deal-cycle comments.

$VERXMedAI 8/10

Vertex Announces Second Quarter 2026 Financial Results

Vertex, Inc. (NASDAQ: VERX) reported Q2 2026 results for the quarter ended June 30, 2026. Total revenue rose 10.5% to $204.0 million, with software subscription revenue up 10.7% to $174.8 million and cloud revenue up 17.9% to $101.7 million. Adjusted EBITDA increased to $51.0 million. Outlook: Q3 revenue $208.0-$211.0 million and adjusted EBITDA $55.0-$57.0 million; FY 2026 revenue $825.0-$830.0 million and adjusted EBITDA $206.0-$210.0 million.

$VERXHigh

Vertex, Inc. (VERX): Results of Operations and Financial Condition

Vertex, Inc. (VERX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 verx-20260803xex99d1.htm EX-99.1 ​ Exhibit 99.1 Vertex Announces Second Quarter 2026 Financial Results KING OF PRUSSIA, PA – August 3, 2026: Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, tod